• Facebook
  • Twitter
  • Instagram
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
MYELOMA360
  • Home
  • News
  • Education
    • Conference Coverage
      • ASCO & EHA 2019
      • EHA 2018
      • ASH 2017
    • CME & Webcasts
  • Events
  • Resources
    • Practice Resources
    • Patient Information
      • Product Education
      • Books
  • Videos
Select Page
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

by MM360 Staff | Apr 21, 2021 | Featured, Webinars

Downloadable Slide Set In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient’s perspective on treatment options. Learners will also get a look ahead at emerging therapeutic...

Recent Content

  • Racial Disparities Seen in US Food and Drug Administration Drug Approval Trials in Multiple Myeloma
  • Sarclisa Combination Shows Positive Results in Patients With Relapsed Multiple Myeloma
  • Trial Kicks Off to Study Experimental CAR-T Cell Therapy in Myeloma
  • Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma
  • The Heparanase/Syndecan-1 Axis in Cancer Progression
  • Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma
  • Computational and Mechanistic Study of the Therapeutic Potential of Compound Formononetin in Preventing Mast Cell Activation and IgE Production in Food Anaphylaxis
  • Transcriptome and regulome signatures of multiple myeloma induced by bone marrow stromal cells
  • One-Year Comparison of Body Composition in a Cohort of Patients with Multiple Myeloma
  • Blocking the PCNA/NKp44 Checkpoint to Stimulate NK Cell Responses to Multiple Myeloma
  • Login/Register
  • Terms & Conditions
  • About
  • Expert Panel
  • Contact Us
  • Facebook
  • Twitter
  • Instagram
©2016-2021 MYELOMA360 & MindWrap Medical, LLC